Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

By Yahoo! Finance | Aug 1, 2024 at 01:47 PM EST

Agios Pharmaceuticals announced results from a Phase 3 study on mitapivat for children with PK deficiency. The drug did not meet the primary endpoint, but showed positive results in reducing transfusions and improving hemoglobin levels. The company plans to release more data in 2025.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.